Read this manager's filing book
Disclosed positions
Decheng Capital LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- CG ONCOLOGY INC
- Ticker
- CGON
- Class
- COM
- Reported value
- $452,707,083
- Reported amount
- 6,371,669
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001104659-26-096837Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| CG ONCOLOGY INC | CGON | COM | $452,707,083 | 6,371,669 | SH | None |
| Nuvation Bio Inc. | NUVB | COM | $147,421,214 | 25,954,439 | SH | None |
| AARDVARK THERAPEUTICS INC | AARD | COM | $22,563,642 | 3,917,299 | SH | None |
| Aclaris Therapeutics, Inc. | ACRS | COM | $21,380,783 | 4,041,736 | SH | None |
| Upstream Bio Inc. | UPB | COM | $18,856,087 | 2,724,868 | SH | None |
| Arcus Biosciences, Inc | RCUS | COM | $14,329,137 | 464,779 | SH | None |
| Equillium Inc. | EQ | COM | $14,231,386 | 4,447,308 | SH | None |
| REVOLUTION MEDICINES INC(NSM) | RVMD | COM | $9,863,476 | 52,667 | SH | None |
| Lyell Immunopharma, Inc. | Unresolved | COM | $9,723,303 | 692,050 | SH | None |
| BeyondSpring Inc. | BYSI | SHS | $6,651,229 | 3,800,702 | SH | None |
| Zentalis Pharmaceuticals Inc. | ZNTL | COM | $6,418,136 | 1,323,327 | SH | None |
| NEWAMSTERDAM PHARMA CO NV | NAMS | COM | $5,994,700 | 176,887 | SH | None |
| Pyxis Oncology, Inc (formerly Apexigen) | PYXS | COM | $983,698 | 326,810 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COM | $625,200 | 20,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.